Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine effect on AT-527 PK in healthy adults
NCT04784000Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoint: Pharmacokinetics (PK) of AT-527 at Day 26. Started Mar 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04784000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04784000.